Clinical Trial Update: Open Label Safety & Pharmacodynamic Study 24Wk w/DIO-902 Combo w/Metformin & Atorvastatin in T2DM Patients [Phase 2, Phase 3]

View source ↗

Summary

Open-label safety and pharmacodynamic study of DIO-902 in combination with Metformin and Atorvastatin for Type 2 Diabetes has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• DIO-902 (DIO-902)
• atorvastatin (atorvastatin)
• metformin (metformin)

Snippet

Sponsor: DiObex | Conditions: Type 2 Diabetes | Phase 2, Phase 3 | Status: TERMINATED